Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMAD: MIS and Deferoxamine in ICH
NCT07162363Phase 3Not yet recruiting
- Sponsor
- University of Illinois Chicago
- Start
- Mar 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of deferoxamine in intracerebral hemorrhage (ICH), sponsored by University of Illinois Chicago. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
deferoxamine
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on NCT07162363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07162363.